var data={"title":"Bismuth subsalicylate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bismuth subsalicylate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7521?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bismuth-subsalicylate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bismuth subsalicylate: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=bismuth-subsalicylate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bismuth subsalicylate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758285\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bismatrol Maximum Strength [OTC];</li>\n      <li>Bismatrol [OTC];</li>\n      <li>Diotame [OTC] [DSC];</li>\n      <li>Geri-Pectate [OTC];</li>\n      <li>Kao-Tin [OTC];</li>\n      <li>Peptic Relief [OTC];</li>\n      <li>Pepto-Bismol InstaCool [OTC];</li>\n      <li>Pepto-Bismol To-Go [OTC];</li>\n      <li>Pepto-Bismol [OTC];</li>\n      <li>Pink Bismuth [OTC];</li>\n      <li>Stomach Relief Max St [OTC];</li>\n      <li>Stomach Relief Plus [OTC];</li>\n      <li>Stomach Relief [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758290\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiarrheal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758326\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diarrhea/dyspepsia:</b> Oral: ~524 mg every 30 to 60 minutes or 1,050 mg every 60 minutes as needed for up to 2 days (maximum: ~4,200 mg [8 doses (regular strength); 4 doses (maximum strength)]/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea prophylaxis (off-label use):</b> Oral: ~524 mg four times daily with meals and at bedtime during period of risk (ACG [Riddle 2016]; CDC 2018; IDSA [Hill 2006]). <b>Note:</b> Safety has not been established for periods &gt;3 weeks (CDC 2018); some experts do not recommend use for trips exceeding 2 weeks in duration (ACG [Riddle 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea treatment (off-label use):</b> Oral: ~524 mg every 30 to 60 minutes as needed up to 8 doses/24 hours (ACG [Riddle 2016]; Castelli 2006; Hill 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Helicobacter pylori</b></i>\n      <b> eradication (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bismuth quadruple therapy: </i>300 mg 4 times daily in combination with tetracycline 500 mg 4 times daily, either metronidazole 500 mg 3 or 4 times daily or 250 mg 4 times daily, and standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758325\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=bismuth-subsalicylate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bismuth subsalicylate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diarrhea/dyspepsia:</b> Children &ge;12 years and  Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758327\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758328\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30124395\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758340\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol Maximum Strength: 525 mg/15 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Pectate: 262 mg/15 mL (355 mL) [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol: 262 mg/15 mL (118 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 525 mg/15 mL (237 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief Max St: 525 mg/15 mL (237 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief Plus: 525 mg/15 mL (240 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as subsalicylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol: 262 mg/15 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Pectate: 262 mg/15 mL (355 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kao-Tin: 262 mg/15 mL (236 mL, 473 mL) [contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg/15 mL (237 mL) [sugar free; contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol: 262 mg/15 mL (473 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg/15 mL (236 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg/15 mL (237 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 262 mg/15 mL (237 mL, 355 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 527 mg/30 mL (240 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol InstaCool: 262 mg [sugar free; contains saccharin sodium; peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 262 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 262 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as subsalicylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol: 262 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diotame: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol To-Go: 262 mg [sugar free; contains fd&amp;c red #40 aluminum lake, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 262 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758288\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758330\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Shake liquids well prior to use. Chew tablets thoroughly or allow to dissolve in the mouth before swallowing. Nonchewable tablets should be swallowed whole with a full glass of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758294\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diarrhea:</b> To control diarrhea, reduce number of bowel movements, and firm stool.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dyspepsia:</b> Relief of gas, upset stomach, indigestion, heartburn, and nausea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758295\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Helicobacter pylori eradication; Traveler's diarrhea prophylaxis; Traveler's diarrhea treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758283\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kaopectate may be confused with Kayexalate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Maalox Total  Relief is a different formulation than other Maalox liquid antacid products which contain aluminum hydroxide, magnesium hydroxide, and simethicone.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Canadian formulation of Kaopectate does not contain bismuth; the active ingredient in the Canadian formulation is attapulgite.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758303\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined; subsalicylate formulation: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, confusion, depression, headache, slurred speech</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Fecal discoloration (grayish black; impaction may occur in infants and debilitated patients), tongue discoloration (darkening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle spasm, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss, tinnitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758300\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">OTC labeling: When used for self-medication, do not use if you are allergic to salicylates or are taking other salicylates; have an ulcer, bleeding problem or bloody/black stool</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758301\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Bismuth products may be neurotoxic with very large doses. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC use): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use subsalicylate. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their health care provider if these occur. A temporary harmless darkening of the stool and/or tongue may occur with use. Contact a health care provider before use if fever or mucus in the stool occurs. Discontinue use and contact health care provider if any of the following occur: diarrhea lasts &gt;2 days or other symptoms lasts &gt;14 days, diarrhea with a fever, symptoms get worse, hearing loss, or ringing in the ears.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758310\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758307\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101044&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Bismuth Subsalicylate may decrease the serum concentration of Tetracyclines.  Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758298\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Following oral administration, bismuth and salicylates cross the placenta. The use of salicylates in pregnancy may adversely affect the newborn (Lione, 1988). Use during pregnancy is not recommended (Mahadevan 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758299\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low amounts of salicylates enter breast milk; refer to the aspirin monograph for additional information (Bar-Oz, 2004). A case report describes bowel obstruction in a breast-fed infant whose mother applied a bismuth-containing ointment to her nipples prior to breast-feeding (Anonymous 1974).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758329\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Drink plenty of fluids to help prevent dehydration caused by diarrhea. Some products may contain phenylalanine, potassium, and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758316\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bismuth subsalicylate exhibits both antisecretory and antimicrobial action. This agent may provide some anti-inflammatory action as well. The salicylate moiety provides antisecretory effect and the bismuth exhibits antimicrobial directly against bacterial and viral gastrointestinal pathogens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758318\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Bismuth: &lt;1%; Subsalicylate: &gt;80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Salicylate: V<sub>d</sub>: 170 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Bismuth and salicylate: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Bismuth subsalicylate is converted to bismuth and salicylic acid in the GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Bismuth: 21 to 72 days; Salicylate: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Bismuth: Urine and biliary; Salicylate: Urine (10% excreted unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758342\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Bismuth Subsalicylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">262 mg (30): $1.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Kao-Tin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">262 mg/15 mL (236 mL): $3.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758344\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bisbacter (CO);</li>\n      <li>Bismucar (PE);</li>\n      <li>Bismutol (EC);</li>\n      <li>Bitni X Forte Suspension (IL);</li>\n      <li>Facidmol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gastro-Bismol (TH);</li>\n      <li>Gastro-Bismol L (TH);</li>\n      <li>Kalbeten (IL);</li>\n      <li>Peptolite (IL);</li>\n      <li>Pink Bismuth (IL);</li>\n      <li>Stobiol (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Bulkowstein M, Benyamini L, et al, &quot;Use of Antibiotic and Analgesic Drugs During Lactation,&quot; <i>Drug Saf</i>, 2003, 26(13):925-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/14583068/pubmed\" target=\"_blank\" id=\"14583068\">14583068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents. <i>Digestion</i>. 2006;73(suppl 1):109-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/16498259/pubmed\" target=\"_blank\" id=\"16498259\">16498259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007; 102(8):1808-1825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connor BA. Travelers&rsquo; diarrhea. In: Centers for Disease Control and Prevention. CDC Health Information for International Travel 2016. New York, NY: Oxford University Press; 2016. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/travelers-diarrhea</a>. Updated July 10, 2015. Accessed February 13, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Health and Human Services, Food and Drug Administration, &ldquo;Antidiarrheal Drug Products for Over-the-Counter Human Use; Final Monograph, (21 CFR Parts 310, 335, 357, 369),&rdquo; <i>Fed Regist</i>, April 17, 2003, 18869-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/10177739/pubmed\" target=\"_blank\" id=\"10177739\">10177739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Health and Human Services, Food and Drug Administration, &ldquo;Labeling for Oral and Rectal Over-the-Counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning; Final Rule (29 CFR Part 201),&rdquo; <i>Fed Regist</i>, April 17, 2003, 18861-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/10177739/pubmed\" target=\"_blank\" id=\"10177739\">10177739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drumm B, Sherman P, Karmali M, et al, &ldquo;Treatment of <i>Campylobacter pylori</i>-Associated Antral Gastritis in Children With Bismuth Subsalicylate and Ampicillin,&rdquo; <i>J Pediatr</i>, 1988, 113(5):908-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/3183851/pubmed\" target=\"_blank\" id=\"3183851\">3183851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham DY, Lew GM, Evans DG, et al, &ldquo;Effect of Triple Therapy (Antibiotics Plus Bismuth) on Duodenal Ulcer Healing,&rdquo; <i>Ann Intern Med</i>, 1991, 115(4):266-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/1854110/pubmed\" target=\"_blank\" id=\"1854110\">1854110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham DY, Lew GM, Klein PD, et al, &ldquo;Effect of Treatment of <i>Helicobacter pylori</i> Infection on the Long-Term Recurrence of Gastric or Duodenal Ulcer,&rdquo; <i>Ann Intern Med</i>, 1992, 116(9):705-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/1558340/pubmed\" target=\"_blank\" id=\"1558340\">1558340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill DR, Ericsson CD, Pearson RD, et al; Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(12):1499-1539.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17109284/pubmed\" target=\"_blank\" id=\"17109284\">17109284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Ingestion of Bismuth-Containing Ointment by a Breast-Fed Infant,&quot; <i>Mt Sinai J Med</i>, 1974, 41(3):498-501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/4545567/pubmed\" target=\"_blank\" id=\"4545567\">4545567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leussnik BT, Nagelkerke JF, van der Water B, et al, &ldquo;Pathways of Proximal Tubular Cell Death in Bismuth Nephrotoxicity,&rdquo; <i>Toxicol Appl Pharmacol</i>, 2002, 180(2):100-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/11969377/pubmed\" target=\"_blank\" id=\"11969377\">11969377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lione A, &quot;Nonprescription Drugs as a Source of Aluminum, Bismuth, and Iodine During Pregnancy,&quot; <i>Reprod Toxicol</i>, 1987-8, 1(4):243-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2980389/pubmed\" target=\"_blank\" id=\"2980389\">2980389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, &quot;Gastrointestinal Medications in Pregnancy,&quot; <i>Best Pract Res Clin Gastroenterol</i>, 2007, 21(5):849-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17889812/pubmed\" target=\"_blank\" id=\"17889812\">17889812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ormand JE and Talley NJ, &ldquo;<i>Helicobacter pylori</i>: Controversies and an Approach to Management,&rdquo; <i>Mayo Clin Proc</i>, 1990, 65(3):414-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2179647/pubmed\" target=\"_blank\" id=\"2179647\">2179647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepto-Bismol (bismuth subsalicylate) liquid [product labeling]. Cincinnati, OH: Procter &amp; Gamble.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soriano-Brucher HE, Avendano P, O'Ryan M, et al, &ldquo;Use of Bismuth Subsalicylate in Acute Diarrhea in Children,&rdquo; <i>Rev Infect Dis</i>, 1990, 12(Suppl 1):51-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    What to do about traveller's diarrhoea. <i>Drug Ther Bull</i>. 2002;40(5):36-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/12053829/pubmed\" target=\"_blank\" id=\"12053829\">12053829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101044 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27758285\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F27758290\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F27758326\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F27758325\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F27758327\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F27758328\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F30124395\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27758340\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F27758288\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27758330\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F27758294\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27758295\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27758283\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27758303\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F27758300\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F27758301\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27758310\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27758307\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27758298\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F27758299\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F27758329\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F27758316\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F27758318\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27758342\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27758344\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101044|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bismuth-subsalicylate-patient-drug-information\" class=\"drug drug_patient\">Bismuth subsalicylate: Patient drug information</a></li><li><a href=\"topic.htm?path=bismuth-subsalicylate-pediatric-drug-information\" class=\"drug drug_pediatric\">Bismuth subsalicylate: Pediatric drug information</a></li></ul></div></div>","javascript":null}